# Pharmacokinetics, Efficacy and Tolerability of BIA 2-093

> **NCT02170064** · PHASE2 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 35 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** BIA 2-093 (Eslicarbazepine acetate)

## Key facts

- **NCT ID:** NCT02170064
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2006-04
- **Final completion:** 2006-04
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2017-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02170064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02170064, "Pharmacokinetics, Efficacy and Tolerability of BIA 2-093". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02170064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*